Valuation: Insulet Corporation

Market Cap 9.79B 8.47B 7.91B 7.26B 13.65B 932B 13.86B 92.79B 36.42B 467B 36.77B 35.96B 1,544B P/E 2026 *
22.9x
P/E 2027 * 18.5x
Enterprise Value 9.84B 8.51B 7.95B 7.29B 13.71B 936B 13.93B 93.23B 36.59B 469B 36.94B 36.13B 1,551B EV / Sales 2026 *
2.99x
EV / Sales 2027 * 2.52x
Free-Float
97.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.34%
1 week-14.62%
Current month-14.62%
1 month-12.62%
3 months-11.99%
6 months-41.65%
Current year-50.33%
1 week 126.4
Extreme 126.4
172.1
1 month 126.4
Extreme 126.4
172.92
Current year 126.4
Extreme 126.4
299.8
1 year 126.4
Extreme 126.4
354.88
3 years 125.82
Extreme 125.82
354.88
5 years 125.82
Extreme 125.82
354.88
10 years 30.69
Extreme 30.69
354.88
Manager TitleAgeSince
Chief Executive Officer 55 28/04/2025
Director of Finance/CFO 53 30/09/2025
Compliance Officer 50 01/12/2022
Director TitleAgeSince
Chairman 61 01/01/2019
Director/Board Member 61 27/07/2015
Director/Board Member 59 10/08/2017
Date Insider Type Main position Quantity % Market Cap.
8/1/26 A Tax

Head of Human Resources

-244 0.0003%
7/1/26 A Free

Director

1,355 0.0019%
7/1/26 A Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+1.34%-14.62%-53.49%-45.88% 9.79B
-0.14%+2.00%-18.36%-0.59% 187B
+1.44%+2.07%-4.47%+2.88% 112B
-1.40%+2.93%+15.11%+71.75% 61.15B
+0.65%+3.91%+37.08%+53.44% 54.39B
-0.12%+6.79%-5.77%-35.74% 48.17B
+2.08%+1.56%+10.93%-29.94% 31.98B
+2.09%-10.31% - - 30.91B
+1.57%+3.85%+47.20%-6.50% 24.92B
+2.45%+3.97%+0.52%+4.99% 23.14B
Average +1.00%-0.16%+3.19%+1.60% 58.26B
Weighted average by Cap. +0.55%+1.74%-0.45%+7.85%

Financials

2026 *2027 *
Net sales 3.29B 2.85B 2.66B 2.44B 4.59B 313B 4.66B 31.18B 12.24B 157B 12.36B 12.09B 519B 3.75B 3.25B 3.03B 2.78B 5.23B 357B 5.31B 35.57B 13.96B 179B 14.1B 13.79B 592B
Net income 429M 371M 346M 318M 598M 40.82B 607M 4.06B 1.6B 20.46B 1.61B 1.58B 67.64B 536M 464M 433M 397M 747M 51.03B 759M 5.08B 1.99B 25.58B 2.01B 1.97B 84.56B
Net Debt 46.14M 39.91M 37.27M 34.19M 64.31M 4.39B 65.33M 437M 172M 2.2B 173M 169M 7.28B -338M -292M -273M -250M -471M -32.16B -479M -3.2B -1.26B -16.12B -1.27B -1.24B -53.3B
Logo Insulet Corporation
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.7%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.3%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2025, the group had 2 production sites located in the United States and in China. The United States account for 72.2% of net sales.
Employees
5,400
Date Price Change Volume
07/08/26 $141.17 +1.34% 1,591,344
06/08/26 $139.30 +4.53% 3,249,442
05/08/26 $133.26 -20.12% 7,177,704
04/08/26 $166.82 -1.70% 1,749,128
03/08/26 $169.70 +2.63% 1,408,011
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
141.17USD
Average target price
171.91USD
Spread / Average Target
+21.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock